LifeMD Inc NASDAQ: LFMD
Consumer Staples : Personal Care Products | Small Cap BlendCompany profile
LifeMD, Inc. is a direct-to-patient telehealth company, which provides comprehensive virtual healthcare. The Company has two segments: Telehealth and WorkSimpli. Telehealth segment is engaged in telehealth platform, which integrates a clinician-centric electronic medical record system, algorithms for case-load balancing and scheduling, customer relationship management functionality, remote and in-home lab testing, and digital prescription capabilities, patient-provider audio/video interfacing, cloud pharmacy fulfillment, and more. Its technology platform, combined with its 50-state affiliated provider network, enables the management of virtual treatment offerings and complex patient journeys for hundreds of conditions spanning men’s and women’s health, dermatology, urgent, and primary care, chronic care management and other. WorkSimpli segment operates PDFSimpli, which is an online software as a service platform that allows users to create, edit, convert, sign and share PDF documents.
Ran across the latest filing in the LIFEMD, INC et al v. LAMARCO et al case. Seems that Lamarco's lawyers got a smackdown on their "Motion to Reconsider its Motion to Dismiss" - the court responded with a "DENIED" in capital letters.
One statement that stood out of the filing was:
Wow. Can you spell LifeMD without Life....which there doesn't seem to be much around here recently.
Just noticed that last week that Judge Stickman is allowing the LifeMD case against Lamarco and Culper to continue - albeit two counts being dismissed. The remaining counts are basically along the lines of defamation and libel that has the potential to set some legal precedents...and not in the favor of those making negative "opinions". Very interesting read in the court filings.
The remaining counts:
- I: Defamation
- II: Trade Libel
- III: False Light
- V: Deceptive Trade Practices
- VI: Unfair Competition
- VIII: Aiding and Abetting
Here's the court filing saying that the case will proceed and NOT be dismissed as Culper/Lamarco had tried to argue. This should be interesting. Lots of "activist investors" short on a stock publishing similar articles that could potentially be in for some further investigation.
“ 8:00a ET 12/23/2021 - Dow Jones
Press Release: LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
NEW YORK, Dec. 23, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD/LFMDP), a leading direct-to-patient telehealth company, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.622483 per share.
The preferred dividend will be paid on January 14, 2022, to holders of record at the close of business on January 4, 2022. ”
LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States. The company provides ShapiroMD, a medical device for male and female hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; Nava MD, a female-oriented tele-dermatology and skincare brand that would offer virtual medical treatment from dermatologists and other providers; and iNR Wellness MD, a supplement for immune and digestive support. It also offers PDFSimpli, an online software-as-a-service platform that allows users to create, edit, convert, sign, and share PDF documents. LifeMD sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is based in New York, New York.
“ Liquidity Evaluation
As of September 30, 2021, the Company has an accumulated deficit approximating $122.9 million and has experienced significant losses from its operations. Although the Company is showing significant positive revenue trends, the Company expects to incur further losses through the end of 2022."
"Reverse Stock Split
On October 9, 2020, the Company filed a Certificate of Amendment to its Articles of Incorporation with the Secretary of State of Delaware (the “Amendment”) in order to effectuate a 1-for-5 reverse stock split of the Company’s issued and outstanding shares of common stock (the “Reverse Split” or “Split”). The Reverse Split was approved by the Financial Industry Regulatory Authority (FINRA) and became effective in the market on October 14, 2020."
"On February 11, 2021, the Company consummated the closing of a private placement offering (the “February 2021 Offering”), whereby pursuant to the securities purchase agreement (the “February 2021 Purchase Agreement”) entered into by the Company and certain accredited investors on February 11, 2021 the Investors purchased 608,696 shares of the Company’s common stock par value $0.01 per share at a purchase price of $23.00per share for aggregate gross proceeds of approximately $14.0 million (the “Purchase Price”). The Purchase Price was funded on the closing date and resulted in net proceeds to the Company of approximately $13.5 million after deducting fees payable to the placement agent and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds to fund growth initiatives, as well as for general corporate purposes.
On June 1, 2021, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with a financial institution (the “Purchaser”), pursuant to which the Company sold and issued: (i) a senior secured redeemable debenture (the “Debenture”) in the aggregate principal amount of $15.0 million (the “Aggregate Principal Amount”), and (ii) warrants to purchase up to an aggregate of 1,500,000 shares of the Company’s common stock at an exercise price of $12.00 per share (the “Warrant”) of which 500,000 warrants were issued to the Purchaser upon closing with the remaining 1,000,000 warrants only issued to the Purchaser in increments of 500,000 if the Debenture remains outstanding for twelve and twenty four months, respectively, following the closing date of the Purchase Agreement. The Warrant has a term of three years, and the Debenture has a maturity date of three years. The Debenture may be paid fully or in part by the Company at any time prior to maturity without penalty to the Company. The Company received gross proceeds of $15.0 million and intends to use such proceeds for working capital, growth investment and general corporate purposes. In October 2021, the Company used a portion of the net proceeds from the October 4, 2021 Preferred and Common Stock Offerings noted below to pay the $15.0 million outstanding on the June 1, 2021 Purchase Agreement.
On June 8, 2021, the Company filed a shelf registration statement on Form S-3 under the Securities Act of 1933, or “Securities Act”, which was declared effective on June 22, 2021 (the “2021 Shelf”). Under the 2021 Shelf at the time of effectiveness, the Company had the ability to raise up to $150 million by selling common stock, preferred stock, debt securities, warrants and units. In conjunction with the 2021 Shelf, the Company also entered into an At Market Issuance Sales Agreement (the “ATM Sales Agreement”) with B. Riley Securities, Inc. (“B. Riley”) and Cantor Fitzgerald & Co. (“Cantor”, and collectively the “Agents”) relating to the sale of its common stock. In accordance with the terms of the ATM Sales Agreement, the Company may, but is not obligated to, offer and sell, from time to time, shares of common stock having an aggregate offering price of up to $60million, through or to the Agents, acting as agent or principal. Sales of common stock, if any, will be made by any method permitted that is deemed an “at the market offering” as defined in Rule 415 under the Securities Act. The Company intends to use any net proceeds from the sale of securities for our operations and for other general corporate purposes, including, but not limited to, capital expenditures, general working capital and possible future acquisitions. There were 70,786 shares of common stock sold under the ATM Sales Agreement as of September 30, 2021 and net proceeds received were $493,481. The Company had approximately $59.5 million available under the ATM Sales Agreement and $90 million available under the 2021 Shelf as of September 30, 2021.
In September 2021, the Company entered into two underwriting agreements (the “Preferred Underwriting Agreement” and “the Common Underwriting Agreement”) with B. Riley Securities, Inc. (“B.Riley”). Pursuant to the Preferred Underwriting Agreement, the Company agreed to sell 1,400,000 shares of its 8.875% Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share, (the “Series A Preferred Stock”) at a public offering price of $25.00 per share, prior to deducting underwriting discounts and commissions and estimated offering expenses (the “Preferred Stock Offering”). In addition, the company granted the underwriters an option to purchase up to an additional 210,000 shares of Series A Preferred Stock within 30 days. Under the Common Underwriting Agreement, the Company agreed to sell to B. Riley 3,833,334 shares of common stock (including 500,000 shares pursuant to B. Riley’s option) (the “Common Shares”), par value $0.01 per share, of the Company at a public offering price of $6.00 per share of common stock, prior to deducting underwriting discounts and commissions and estimated offering expenses (the “Common Stock Offering”). The Preferred Stock Offering and Common Stock Offering collectively referred to as the “Offerings”, closed on October 4, 2021. Net proceeds after deducting the underwriting discounts and commissions, the structuring fee and estimated offering expenses payable by the Company, but before repayment of debt, from the Offerings was approximately $55.3 million. The Company used a portion of the net proceeds to pay the $15.0 million outstanding on the June 1, 2021 Purchase Agreement and intends to use the remaining net proceeds to fund the segregated dividend account, for working capital and general corporate purposes including, but not limited to, new patient customer acquisition expenses and capital expenditures.
The Company will pay cumulative distributions on the Series A Preferred Stock, from the date of original issuance, in the amount of $2.21875 per share each year, which is equivalent to 8.875% of the $25.00 liquidation preference per share. Dividends on the Series A Preferred Stock will be payable quarterly in arrears, on or about the 15th day of January, April, July and October of each year. The first dividend on the Series A Preferred Stock sold in this offering will be paid on or about January 15, 2022."”
“ COVID-19 Vaccine Mandate
We are making preparations to comply with a rule issued by the Occupational Safety and Health Administration (“OSHA”) to ensure that our employees are fully vaccinated against COVID-19 by January 4th or that they test negative for COVID-19 at least once per week. Employees must receive time off to get vaccinated and sick leave to recover from any side effects. Any unvaccinated employees must wear face coverings while at work. We are in the process of assessing the financial and staffing impact of these requirements.”
“4:05p ET 11/10/2021 - Dow Jones
Press Release: LifeMD Reports Q3 2021 Revenue Up 127% to Record $24.9 Million and 24% Sequential Improvement in Adjusted EBITDA
LifeMD Reports Q3 2021 Revenue Up 127% to Record $24.9 Million and 24% Sequential Improvement in Adjusted EBITDA
-- Revenue increased to a record $24.9 million, up 127% from the same year-ago period -- 24% sequential improvement in Adjusted EBITDA versus prior quarter -- 93% of Q3 2021 revenue generated by subscriptions, up from 61% in the same year-ago period -- Total telehealth order volume grew 153% to 232,293
NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, reported results for the third quarter ended September 30, 2021. All figure comparisons are to the same year-ago quarter unless otherwise noted. Management will host a conference call today at 5:00 p.m. Eastern time to discuss the results.
Q3 Financial Highlights
-- Record revenue of $24.9 million, up 127% -- 93% of revenue generated by subscriptions, up from 61% -- Gross profit totaled $19.9 million, or 80% of net revenues, up 113% -- Adjusted EBITDA of $(9.0) million, a 24% sequential improvement versus the prior quarter (see definition of this non-GAAP financial measure and reconciliation to GAAP, below) -- Adjusted EPS of $(0.36), a 25% sequential improvement versus the prior quarter (see definition of this non-GAAP financial measure and reconciliation to GAAP, below)
Q3 Operational Highlights
-- Achieved significant leverage improvement in marketing investment expenses, reducing marketing spend as a percentage of revenue to 81% versus 100% in the prior quarter, with continued leverage expected. -- Total unique patients and customers served nationwide surpassed 427,000 during the quarter, up from over 360,000 in the prior quarter. -- Telemedicine orders increased 153% to approximately 232,000. -- Appointed seasoned investor and private equity professional Naveen Bhatia to its Board of Directors. Most notably, Mr. Bhatia served as Senior Managing Director in the Tactical Opportunities group of Blackstone for nearly a decade and as director of numerous public and private companies.
-- Completed a public offering of 3,833,334 shares of its common stock and 1,400,000 shares of its 8.875% Series A Cumulative Perpetual Preferred Stock raising approximately $55 million in net proceeds. -- Announced transformational launch of our 50-state Virtual Primary Care business, which we expect to drive increased satisfaction with our existing patients and open the door to many new treatment areas for LifeMD.
Key Performance Metrics
($ in 000s) Three Months Ended September 30 Y-o-Y --------------------------------------- -------- Key Performance Metrics 2021 2020 % Growth -------------- ---------------- --------------- -------- Revenue -------------- Telehealth $ 18,541 $ 9,438 96% WorkSimpli $ 6,406 $ 1,568 309% Total Revenue $ 24,947 $ 11,006 127% Subscription Revenue as % of Total 93% 61% 52% Platform Contribution $ 17,478 $ 8,136 115% Telehealth Volume -------------- Total Telehealth Orders 232,293 91,955 153% WorkSimpli -------------- Active Subscribers 139,248 35,240 295%
"Q3 was an especially strong quarter for our business. Not only did we experience record revenue of $24.9 million supported by record demand for our telehealth products and services, but we demonstrated the early stages of our ability to enhance our profitability while growing our top-line aggressively. I am especially proud of our team's ability to drive meaningful sequential improvement in our Adjusted EBITDA and expect these sequential improvements to continue as we push toward achieving our goal of Adjusted EBITDA break-even by the fourth quarter of 2022," said Justin Schreiber, CEO of LifeMD. "Additionally, I, along with the entire team, am extremely excited about the recently announced launch of Virtual Primary Care which we believe is a game-changing step in the evolution of our company as we continue to become a disruptive force in healthcare. We expect this launch to not only diversify and strengthen our telehealth offering but also to drive meaningful long-term improvements in our already strong unit economics and retention, all while taking the holistic care we provide patient customers to an entirely new level."
LifeMD CFO Marc Benathen, commented: "As we've committed to previously, we remain laser-focused on not only aggressively growing our top-line, but also scaling with gradually improving profitability. We began to demonstrate our ability to execute upon that commitment this quarter by delivering a 24% sequential improvement in Adjusted EBITDA driven by strong retention metrics in our telehealth business and further optimization of our media spend. At the same time, we grew our revenue by 127% versus prior year. Following the quarter end, we successfully completed an over-subscribed offering of Preferred and Common Stock which has put LifeMD in its strongest capital position ever and we believe can capitalize LifeMD through profitability while continuing to invest in our aggressive growth. We reiterate our expectation of achieving Adjusted EBITDA break-even by the fourth quarter of 2022."
Q3 2021 Financial Summary
-- Revenue increased 127% to a record $24.9 million from $11.0 million in the same year-ago quarter. The WorkSimpli subsidiary, which operates PDFSimpli, an online software-as-a-service (SaaS) platform, increased 309% to $6.4 million. -- Gross profit increased by 113% to $19.9 million, compared to $9.3 million in the same year-ago quarter. Gross margin was 80% as compared to 85% in the year-ago quarter, primarily due to product sales mix and one-time, non-cash write-off of legacy product deposits. -- Platform Contribution, a non-GAAP financial measure, totaled $17.5 million, compared to $8.1 million in the same year-ago period (see definition of this non-GAAP financial measure and reconciliation to GAAP, below). -- Operating expense in the third quarter of 2021 was $32.4 million, up from $29.9 million in the same year-ago quarter with operating leverage improved by 2,300 basis points versus the prior quarter due to significant leverage realized in selling and marketing expense, general and administrative expenses and strong retention metrics. The increase in expense versus prior year was primarily due to increases in selling and marketing expenses of $9.8 million in the quarter, other operating expenses of $272,000, customer services expenses of $275,000, and development costs of approximately $13,000. General and administrative expenses decreased $7.7 million during the quarter driven by a $13.3 million decrease in stock-based compensation expense and included non-cash expenses for stock-based compensation and amortization expenses of $4.8 million. -- Net loss attributable to common stockholders for the third quarter of 2021 was $14.4 million or $(0.54) per share, as compared to a net loss attributable to common stockholders of $24.2 million or $(1.65) per share in the third quarter of 2020. -- Excluding $3.1 million related to stock-based compensation expense, $1.6 million related to the non-cash amortization of debt discount, $0.1 million related to depreciation and amortization expense and $0.2 million related to financing transaction expense, Adjusted EPS, a non-GAAP basis, totaled a loss of $(0.36) per share as compared to a loss of $(0.52) in the same year-ago period. Adjusted EPS improved 25% sequentially versus the prior quarter (see definition of this non-GAAP financial measure and reconciliation to GAAP, below). -- Adjusted EBITDA, a non-GAAP financial measure, totaled a loss of $9.0 million, compared to an adjusted EBITDA loss of $3.8 million in the same year-ago period. Adjusted EBITDA improved 24% sequentially versus the prior quarter (see definition of this non-GAAP financial measure and reconciliation to GAAP, below).
2021 Financial Outlook
The company reiterates its expectation for revenue in the full year of 2021 to total between $90 million and $100 million, which would represent growth of between 141% and 168% over the prior year.
“8:00a ET 11/8/2021 - Globe Newswire
LifeMD Launches Virtual Care Platform, Bringing Accessible, Affordable Healthcare to Patients Nationwide
LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced the launch of its virtual care platform - a quantum leap in healthcare that uses telemedicine to connect patients directly with a doctor anytime, anywhere.
The LifeMD virtual care platform combines best-in-class telehealth technology with in-house physicians to provide care across all 50 states. The platform provides a patient-centric healthcare experience, giving patients direct contact with their personal physicians and with dedicated medical teams who respond quickly to their concerns - all geared toward achieving better health outcomes.
"American healthcare is irretrievably broken. Twenty-five percent of adults in America do not have a primary care physician, and many who do wait months just for appointments, then spend hours in waiting rooms and worry about affording their medical bills. Our new virtual care platform addresses this full-blown crisis - and offers a solution," said LifeMD CEO, Justin Schreiber.
"Our mission is to make healthcare welcoming," said LifeMD Chief Business Officer Corey Deutsch. "At LifeMD virtual care, patients can book their first appointment in minutes and gain access to a dedicated medical team ready to deliver personalized care anywhere, anytime."
LifeMD is strategically sequencing the rollout of the virtual care offering. In the initial phase - commencing today - the platform will be available by invitation. The final stage of the launch, commencing nationwide access for the general public, is set for January 1, 2022.
Patients can access LifeMD's virtual care service through the website or the LifeMD app and by completing a simple onboarding process: A health questionnaire and a virtual meet-and-greet consultation with their new primary care physician. Patients can then access their dedicated medical team, prescription management, and appointments at the click of a button. LifeMD's physicians are board certified and highly regarded by their patients.
"The secret to great care is great doctors," Schreiber noted. "Everyone deserves high-quality healthcare, and our primary care offering is like having a doctor in the family."
In recent months, LifeMD has forged strategic partnerships to bolster the comprehensive virtual care platform announced today. These alliances give LifeMD the ability to offer on-site nurse visits, provide direct-to-patient laboratory and diagnostics testing at preferential pricing for LifeMD members, consolidate patient data in a way that is both patient- and physician-friendly, deliver a best-in-class pharmacy fulfillment and e-prescribing technology platform, and grant immediate access to a nationwide pharmacy network.
"Beyond generalized virtual primary care, the technology platform LifeMD has built to support today's launch enables the ability to scale into hundreds of other conditions," Schreiber said. "There are very few scalable technology platforms like LifeMD's that combine a 50-state physician network, diagnostics, e-pharmacy, in-home sample collection and care and, eventually, continuous monitoring with wearables."
"We stand at the forefront of the paradigm shift transforming global health," Schreiber added. "Since our founding, LifeMD has focused on bringing honesty and transparency to healthcare. Our affiliated providers have treated more than 360,000 patients through branded telehealth services like Rex MD, Shapiro MD, and Nava MD. We are excited to take this leap into primary care."
closed all short term gaps today, best telehealth company at these price levels, heading towards winter health stocks should kick into their cyclical strength imo, life md, life doc, marty traveled back in time to save doc’s life on November 13, 1955. 1.21 gigawatts.
5$ shares … all day long … LFMD
Chart ? Wow ! Is it At bottom LFMD has been crushed from 30 to 7
PR today : Strategic partnership provides LifeMD with a vertically integrated, best-in-class pharmacy fulfillment and e-prescribing technology platform and immediate access to nationwide pharmacy network.
LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced its strategic partnership with Prescryptive Health, a healthcare technology company empowering consumers by improving the way healthcare is delivered. The partnership is expected to accelerate growth for both companies by combining LifeMD’s expanding direct-to-patient telehealth brands and soon-to-launch primary care platform with Prescryptive’s best-in-class digital pharmacy fulfillment and e-prescribing technology platform.
yeah no chance
6$ now and dropping … 30$ target ???
7$ stock now … Geeez LFMD
Awesome....I was tired of waiting for the Victoria's Secret catalog to come in the mailbox.....
Oh....should get some more filings in the LifeMD vs. Lamarco/Culper case this week. Hopefully the court won't block/redact them from being published online.
Facebook and Instagram loaded with RexMD erectile dysfuction ads !!$$$
Some of them very Rated PG-17 or R
Check it out LFMD
I dunno...looks almost even between buying and selling. I think the shorts had a plan and schedule in place with Culper....then people keep buying up the shares....
LFMD doesn't seem to be a favorite of the Little Timmy Sykes crowd:
Short Interest doesn't seem remarkable with a very low days to cover.
Most likely retail investors with weak nerves not willing to weather the storm...
Rated a strong buy right now by one analyst - target $37.50.
I say hang tough...things will improve.
Looks like Life is losing the battle to the shorts
I think all the money is going into petro and shipping right ....my personal board is all red today...
From the looks of the share price....something else is going on.....
Down 7% right now and had dipped to $10.53 today. Rough day.
LFMD update in email alert:
LifeMD (NASDAQ: LFMD) CEO Justin Schreiber: “LifeMD’s Growth and Acceleration Show No Signs of Slowing”
“..Our first quarter of 2021 was not only marked by record topline performance, it also saw us make significant strides in solidifying the infrastructure, which will enable LifeMD to scale efficiently towards longer term profitability....As an industry leader in telehealth customer acquisition, our growth potential remains massive. We are operating in open whitespace of a nascent industry with a total addressable market of nearly a trillion dollars.“
“...We have built a platform that has the ability to support tens if not hundreds of direct to patient telemedicine offerings and seeing the value of our offerings, our patients are overwhelmingly choosing subscription based products and services, which have been fueling our significant sequential growth…..In the last week of the quarter, we launched Nava MD, a direct to patient clinical tele-dermatology services brand for women, which added further diversification to our growing portfolio of companies. Nava MD is our third launch in four years, and we look forward to further developing the brand. In addition, as I've spoken about before, we continue to anticipate launching our namesake LifeMD primary care platform later this summer. We believe this launch, coupled with our very successful current and future conditions specific telemedicine brands will provide LifeMD with a powerful and differentiated end-to-end direct to patient telehealth platform…”
LifeMD (NASDAQ: LFMD) Earnings Highlights: https://bit.ly/2V1FNjL
WALL STREET REPORTER
Wall Street Reporter (Est. 1843) is the leading financial news provider, focused on giving investors direct access to CEO's of promising, publicly-traded companies, and market experts. www.WallStreetReporter.com. Nothing in this news summary shall be construed as investment advice. Quotes/content may be edited for brevity and context. Full disclaimer, and relevant SEC 17B disclosures here: http://bit.ly/39kkE7K
About Wall Street Reporter’s Next Super Stock conference:
Wall Street Reporter's NEXT SUPER STOCK Live! conference is dedicated to featuring select companies that have near-term catalysts in place which can drive transformational growth (and stock appreciation) in the months ahead. Click here to join next livestream event: https://www.wallstreetreporter.com/next-superstock-online-investor-conference/
WALL STREET REPORTER
(212) 871-2057 ext 7
Looking at the delayed trades it's pretty evenly split between buying and selling.
Looks like someone is fishing for stop losses. Any idea what the short interest is on LFMD? I'm too lazy to go digging.
I really think LFMD, telemedicine, and this pandemic really showed the world that you CAN get basic healthcare guidance and maintenance without dragging your infected carcass into a public doctor/hospital setting.
I don't own LFMD but I like it and seriously dislike Culper.